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1.
METHOD AND APPARATUS FOR CANCER
SCREENING
CROSS REFERENCE TO RELATED
APPLICATIONS

This application claims priority from U.S. Provisional
Application Ser. No. 61/284.336, which has a filing date of
Dec. 17, 2009.
10

FIELD OF THE INVENTION

The present invention generally relates to an apparatus and
method for Screening for cancer. In particular, the apparatus
and method for screening for cancer is based on the detection
of pteridine molecules in biological samples, for example,
urine samples.

15

BACKGROUND OF THE INVENTION

Cancer is the second leading cause of death in the United
States. To date, approximately 50% of all neoplasms are
treated with multi-disciplinary cancer treatment. Neoplastic
disorders differ widely in etiology, pathology, and natural
disease history. The principle behind detection at earlier
stages of disease progression yielding higher cure rates
applies to virtually all Solid tumors. As a result, cancer Screen
ing has been an area of elevated research and clinical interest
and has greatly impacted cancer diagnoses and treatments.
Biomarkers are compounds in the body that may be indica
tive of medical conditions or biological states. Hayes et al.
defined a cancer biomarker as "a molecular, cellular, tissue, or
process-based alteration that provides indication of current,
or more importantly, future behavior of cancer.’ See Hayes D
F. Bast RC, Desch CE, et al. Tumor marker utility grading
system: a framework to evaluate clinical utility of tumor
markers. J. Natl. Cancer Inst. 1996, 88, pp. 1456-66. These
biological and physiological indicators could include a broad
range of biochemical entities, such as nucleic acids, proteins,
Sugars, lipids, and Small metabolites, as well as whole cells, in
either specific tissues or in circulation. Today, circulating
cancer cells are becoming a powerful tool in “microscopic'
cancer Screening. Detection of biomarkers, either individu
ally or as larger sets or patterns, can be accomplished by a
wide variety of methods, ranging from biochemical analysis
of blood or tissue samples to biomedical imaging.
Normally, patients are hesitant to damage their organs and
tissues to give samples during the disease diagnosis process.
They may also be reluctant to give blood for diagnostic tests.
Therefore, development of a noninvasive diagnostic tech
nique for early cancer screening is very crucial for all popu
lations. Noninvasive diagnosis involves procedures that do
not penetrate the body mechanically, nor break the skin or
involve penetration through a body cavity. It does not require
an incision into the body or the removal of biological tissue.
Currently, many researchers are focusing on noninvasive
means to diagnose cancer by analyzing cancer biomarkers in
urine, which is more easily collected than tissue or blood
samples.
Recently, pteridine molecules have become a focal point of
cancer screening research. See Rokos K. Rokos H., Frisius
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H., Huefner M., Pteridines in Cancer and Other Diseases,

1983, pp. 153-7: Noronha J. M., Trehan S., Urinary Excretion
of Total Pteridines in Cancer, 1990, pp. 515-8; Murr C.
Widner B. Wirleitner B., Fuchs D., Neopterinas a Marker for
Immune System Activation, Curr. Drug. Metab. 2002, 3, pp.
175-87; Han F., Huynh B. H., Shi H., Lin B., MaY., Pteridine
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Analysis in Urine by Capillary Electrophoresis Using Laser
Induced Fluorescence Detection, Anal. Chem., 1999, 71, pp.
1265-9; Gibbons S. E., Stayton I., Ma Y. Optimization of
Urinary Pteridine Analysis Conditions by CE-LIF for Clini
cal Use in Early Cancer Detection, Electrophoresis, 2009, 30.
pp. 3591-7: Fuchs D. Kramer A., Reibnegger G. et al., Neop
terin and Beta 2-Microglobulin as Prognostic Indices in
Human Immunodeficiency Virus Type 1 Infection, Infection,
1991, 19 (Suppl. 2), pp. S98-S102. Pteridines are a group of
heterocyclic compounds contained in the body and excreted
in the urine. Research into the use of pteridines as cancer
biomarkers investigated the urinary pteridine levels as poten
tial biomarkers for noninvasive diagnosis of cancer. Pte
ridines are naturally occurring heterocyclic compounds
involved in the biosynthetic pathways of cofactors and vita
mins. Research suggests that concentrations of pteridines
found in urine differ between cancer patients and non-cancer
patients. For example, it has been reported that the neopterin/
biopterin ratio differs among cancer patients and non-cancer
patients. See Stea, B. et al., Clin. Chim. Acta, 1981, 113, pp.
231-242, which reported that the neopterin/biopterin level for
cancer patients was 1.6 times that of normal Subjects. Addi
tionally, the amount of pteridine and pattern of expression in
the urine may vary with specific neoplasms and clinical stage.
Thus, urinary pteridine assays have been studied as a potential
cancer Screening method
Analysis of pteridines has been performed with several
techniques, such as thin layer chromatography (TLC), high
performance liquid chromatography (HPLC) combined with
UV or fluorescence detection, and conventional capillary
electrophoresis with laser induced fluorescence detection
(CE-LIF). For example, a method has been reported describ
ing the determination of total oncopterin, neopterin, and biop
terin in human urine using solid phase extraction with 6.7dimethylpterin as internal standard and gradient HPLC with
fluorescence detection. See Tomandlet al., Journal of Sepa
ration Science, Vol. 26, 8, pp. 674-678, June 2003. However,
the detection limit for oncopterin reported in the study is
relatively high at about 1.43 mol/L. Moreover, the reported
urine preparation time is still long (about 2 hr), since the study
utilized full hydrolysis vs. oxidation of the pteridines.
In U.S. Pat. No. 6,576,105 B1 by Yinfa Ma, the inventor
also described a detection method for pteridines in urine
using the conventional CE-LIF technology. Even though the
patented CE-LIF technology has shown promising improve
ments in feasibility for clinical laboratories, the patented CE
LIF technology has limitation on the accuracy and reproduc
ibility because of the complexity of urine samples.
Therefore, there is a need to provide a new and improved
cancer Screening method by pteridine urine detection using
CE-LIF. There is also a need to provide an improved CE-LIF
apparatus for the pteridine urine detection to achieve a non
invasive, sensitive, fast, simple, and cost effective cancer
screening tool.

65

The present invention is directed to a cancer Screening
method. The cancer screening method of the present inven
tion detects pteridine concentration levels in a subject’s bio
logical sample Such as urine. The concentration of the pteri
dine compound in the patient’s biological sample is
compared to an expected concentration of the pteridine com
pound in either a healthy mammal of the same species or in a
cancer-bearing mammal of the same species.

US 9,207,205 B2
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According to some embodiments of the invention, the
inventive cancer Screening method comprises the step of
detecting oncopterin level in a Subject's urine sample.
The inventive method may further comprise the step of
detecting concentration levels of other pteridine to determine
what type(s) of cancer that a subject may develop.
According to some embodiments of the method of the
present invention, a biological sample, e.g., a Subject's urine
sample, is collected and pretreated prior to analysis. Pretreat
ment involves a first step of oxidizing the pteridines in the
sample by exposure to a composition containing an oxidizing
agent. Pteridines are oxidized to their fully oxidized state. In
Some preferred embodiments, the oxidizing agent is iodine.
Pretreatment may involve alkalinization of the pteridine con
taining sample by exposure to an alkaline Solution, which
assists in the extraction of the pteridines from the urine
sample as pteridines have a higher solubility factor in alkaline

5
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Solutions.

According to the method of the present invention, the
sample may be centrifuged and the Supernatant diluted with a
buffer solution in order to prepare the sample for separation
via capillary electrophoresis. The treated Sample is then intro
duced subjected to capillary electrophoresis by using either a
gravimetric, electrokinetic, or pressure injection technique.
The separated sample is then irradiated by a non-polarizing
light Source, and the fluorescence emission is detected by a
fluorescence detection means, such as a photomultiplier tube,

25

concentration sufficient such that at least about 90 wt % of

to collect the fluorescence.

The present invention is further directed to a capillary
electrophoresis lased induced fluorescence (CE-LIF) appara
tus. The CE-LIF employs a combination of lenses, filters, and
irises to enhance stability and reproducibility of the urine
pteridine detection. The lenses, filters, and irises enhance
detection by substantially reducing laser scatter from the
excitation source and from the capillary, thereby producing a
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stable, low noise baseline that enables low limits of detection.

The CE-LIF apparatus employs a combination of a confocal
lens having greater than 10x magnification placed in the
range of 45 to 90 degrees from the laser path to collect and
focus fluorescence emission from the sample. The CE-LIF
apparatus employs at least one physical iris for removing
scattered light either from the filtered non-polarized laser or
from any fluorescence generated by the device. A device
structured with the high magnification confocal lens and iris
yields a very low noise baseline, enabling low limits of detec
tion of pteridines in urine and other samples.
In some embodiments, the inventive apparatus includes 1)
a non-polarized excitation source emitting non-polarized
laser at a non-traditional Solid state laser wavelength. In some
embodiments, the inventive apparatus includes 2) a first fil
tration means for filtering the non-polarized laser. In some
embodiments, the inventive apparatus includes 3) a focal lens
that focuses the filtered, non-polarized laser onto a capillary,
the pathway by which the intended sample is separated and
exposed to the filtered, non-polarized laser via a detection
window on the capillary. In some embodiments, the inventive
apparatus includes 4) a sample holder with a detection win
dow that facilitates the mounting of an electrophoresis capil
lary. In some embodiments, the inventive apparatus includes
5) a capillary electrophoresis device that is capable of sepa
rating the specific compounds of interest (pteridines) within
the samples and delivering the sample to the detection win
dow of the capillary mounted within the sample holder.
In some embodiments, the inventive apparatus includes 6)
a confocal lens greater than 10x magnification placed in the
range of 45 to 90 degrees from the laser path to collect and
focus fluorescence emission from the sample. In some

4
embodiments, the inventive apparatus includes 7) a second
filtration means for filtering non-pteridine fluorescence gen
erated by any compound other than those in the pteridine
family or for filtering background scattering light from the
laser. In some embodiments, the inventive apparatus includes
8) a physical iris for removing any scattering either from the
filtered non-polarized laser or from any fluorescence gener
ated by the device. The physical iris controls the light beam
size and minimizes the scattered light. In some embodiments,
the inventive apparatus includes 9) a detection means for
detecting the filtered fluorescence emission generated by the
pteridines in the samples. In some embodiments, the inven
tive apparatus includes 10) a current to Voltage (I to V) con
verter to communicate the raw output from the electrons from
the compounds of interest undergoing fluorescent decay to
the digital input of the device collecting the output. In some
embodiments, the inventive apparatus includes 11) a control
means for independently controlling the stations of the laser
focal lens, capillary mount, collection lens and detector to
prevent any mechanical cross-talk from one stage to the oth
ers that may adversely affect the resulting data.
Briefly, therefore, the invention is directed to a method of
detecting a pteridine compound concentration in a biological
sample obtained from a mammal, the method comprising
treating the biological sample with an oxidizing agent in a
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said concentration of pteridine compound in the biological
sample is in its fully oxidized State; Subjecting the sample to
capillary electrophoresis using laser-induced fluorescence
(CE-LIF) to cause the oxidized portion of said concentration
of said pteridine compound to emit fluorescent light; detect
ing the emitted fluorescence light; and analyzing the emitted
fluorescence light to determine the concentration of the pte
ridine compound in the biological sample.
The invention is also directed to a method for screening for
cancer in a mammal, the method comprising quantitatively
measuring a concentration of oncopterin (N2-(3-aminopro
pyl) biopterin) in a biological sample from the mammal by
capillary electrophoresis-lased induced fluorescence; and
comparing the concentration of oncopterin (N2-(3-amino
propyl) biopterin) in the sample with the concentration of
oncopterin (N2-(3-aminopropyl) biopterin) in a biological
sample from a healthy mammal of the same species to deter
mine whether the concentrations of oncopterin (N2-(3-ami
nopropyl) biopterin) is significantly elevated or decreased.
In a further aspect, the invention is directed to an apparatus
for determining a concentration of pteridine in a biological
sample, the apparatus comprising an excitation source emit
ting non-polarized laser light capable of inducing the pteri
dine to emit fluorescent light and having a power output of at
least about 1 mW; an electrophoresis capillary having a detec
tion window and being capable of separating the pteridine
from other components of the biological sample; a first opti
cal system for focusing the non-polarized laser light onto the
detection window of the capillary, wherein the first optical
system comprises a focal lens; a light collection device for
collecting fluorescent light emitted from the pteridine in the
biological sample; and a second optical system for magnify
ing fluorescent light emitted from the pteridine and for focus
ing the magnified fluorescent light onto the light collection
device, wherein the second optical system comprises a con
focal lens having a magnification greater than 10x and a
physical iris diaphragm.
Other objects and features of the invention will be in part
apparent and in part pointed out hereinafter.

US 9,207,205 B2
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BRIEF DESCRIPTION OF THE DRAWINGS

TABLE 1

FIG. 1 is a schematic design of the capillary electrophore
sis with laser induced fluorescence detection (CE-LIF) appa
ratus of the present invention.
FIG. 2 is an electropherogram of the eight pteridine stan
dards. The experimental conditions are described in the
Example.
FIG. 3 is a box plot of 6,7-dimethylpterin levels in cancer
urine samples (n=38) and normal urine samples (n=17).
FIG. 4 is a box plot of 6-biopterin levels in cancer urine
samples (n=38) and normal urine samples (n=17).
FIG. 5 is a box plot of 6-hydroxymethylpterin levels in
cancer urine samples (n=38) and normal urine samples
(n=17).
FIG. 6 is a box plot of D-(+)-neopterin levels in cancer
urine samples (n=38) and normal urine samples (n=17).
FIG. 7 is a box plot of pterin levels in cancer urine samples
(n=38) and normal urine samples (n=17).
FIG. 8 is a box plot of isoxanthopterin levels in cancer urine
samples (n=38) and normal urine samples (n=17).
FIG. 9 is a box plot of xanthopterin levels in cancer urine
samples (n=38) and normal urine samples (n=17).
FIG. 10 is a box plot of xanthopterin levels in cancer urine
samples (n=38) and normal urine samples (n=17).
FIG. 11 is a box plot of isoxanthopterin levels in breast
cancer urine samples (n=12), lung cancer urine samples
(n=9), and normal urine samples (n=17).
FIG. 12 is a box plot of xanthopterin levels in breast cancer
urine samples (n=12), lung cancer urine samples (n=9), and
normal urine samples (n=17).
FIG. 13 is a scatter plot of creatinine levels in cancer urine
samples (n=38) and normal urine samples (n=17).
FIG. 14 is an electrophergram generated according to
Example 2.
Corresponding reference characters indicate correspond
ing parts throughout the drawings.
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THE INVENTION

carboxylic acid, and oncopterin ((N'-(3-aminopropyl)

NH

N

DESCRIPTION OF THE EMBODIMENT(S) OF

used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
belongs. All publications, patent applications, patents, and
other references mentioned herein are incorporated by refer
ence in their entirety.
The present invention provides a cancer Screening method
for detecting pteridine levels in a biological sample, e.g., a
urine sample, using capillary electrophoresis-laser induced
fluorescence (CE-LIF) technology.
The major pteridines molecules that are detected in accor
dance with this invention are one or more from among 6.7dimethylpterin, 6-biopterin, D-(+)-neopterin, 6-hydroxym
ethylpterin, pterin, isoxanthopterin, Xanthopterin, pterin-6-
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As shown in Table 1, the above listed molecules all contain
65

a pterin base with a variety of functional groups that can be
bonded to the C6 carbon of the bi-cyclic pterin molecule
forming the pteridine of interest.
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In general, the method of the present invention involves the
following steps:
1) Preparing a urine sample for analysis;
2) Separating the pteridines in the prepared sample by
capillary electrophoresis (CE); and
3) detecting pteridine levels in the sample with laser
induced fluorescence (LIF).
Sample preparation involves oxidation of the pteridines in
the biological sample. The sample is additionally pH adjusted
by alkalinizing the sample. The sample may be centrifuged
and diluted prior to separation by capillary electrophoresis.
The present invention is further directed to an apparatus
that may be used to detect pteridine levels in a biological
sample, e.g., a urine sample, by capillary electrophoresis
laser induced fluorescence (CE-LIF).
I. Sample Preparation
According to some embodiments of the method of the
present invention, a biological sample, e.g., a urine sample,
which is known to contain pteridines is prepared for analysis
via capillary electrophoresis-laser induced fluorescence (CE
LIF).
Pteridines in biological samples generally exist in three
oxidative states. The most reduced biological state is the
tetrahydropteridin form. According to the nomenclature in
the art, a tetrahydropteridin form of biopterin, for example, is
referred to as tetrahydrobiopterin and written as HB in short
hand. An intermediate reduced biological state is the dihy
dropteridin form. According to the nomenclature in the art, a
dihydropteridin form of biopterin is referred to as dihydro
biopterin and written as H-B in shorthand. Accordingly,
reduced compounds are indicated by the prefixes dihydro
tetrahydro-, etc., with numerals indicating the positions of
the additional hydrogen atoms, if known. A tetrahydro-com
pound is assumed to be substituted in the 5, 6, 7, and 8
positions, and a dihydro-compound is assumed to be substi
tuted in the 7 and 8 positions, unless otherwise indicated:
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In accordance with this invention, pteridines in the biologi
cal sample, e.g., urine sample, are oxidized to their fully
oxidized state. It has been discovered that fully oxidized
pteridines produce a simpler sample matrix with less back
ground interference, and are easily prepared and quantified.
The oxidation treatment is sufficient to quantitatively oxidize
pteridines that may be in their lower (e.g., dihydro or tetrahy
dro) redox state in the sample to their fully oxidized state. In
one aspect, the oxidation treatment is sufficient to oxidize
tetrahydro and dihydropteridines into the fully oxidized state
Such that the concentration of one or more pteridine com
pounds being analyzed that exist in the sample in their fully
oxidized state comprise at least about 90 wt % (or 95 wt %, or
99 wt %, or 99.9 wt %) of the total of such pteridines in the
sample. Stated another way, the total concentration of the
pteridine compounds being analyzed that exist in the sample
in the tetrahydro or dihydro (or other) reduced states is less
than about 10 wt % of the total of such pteridine compounds
in the sample. Preferably, oxidative treatment is sufficient to
oxidize the pteridines being analyzed such that at least about
95 wt % of the total of such pteridines in the sample are in the
fully oxidized form (e.g., less than about 5 wt % of such
pteridines are in the, e.g., tetrahydro or dihydro, reduced
states), even more preferably at least about 99 wt % of the
total of such pteridines in the sample are in the fully oxidized
pteridines are in the fully oxidized form. It has been discov
ered that the best results are achieved for early cancer screen
ing if inaccordance with this invention all or essentially all of
the pteridines are fully oxidized, by which it is meant 100 wt
% or nearly 100% of the pteridine concentration, and it is
meant of all the several known pteridine species.
Accordingly, the invention involves treating the biological
sample with an oxidizing agent in a concentration Sufficient
such that at least about 90 wt % of the concentration of a

shown below:
N

ul

form, such as at least about 99.9 wt % of the total of such
45
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Biological samples may comprise pteridines in a fully oxi
dized State. According to the nomenclature in the art, the fully
oxidized form of biopterin is simply referred to as biopterin
and written as B in shorthand. The structures of biopterin in its
fully oxidized state, as the dihydrobiopterin intermediate
reduced state, and the fully reduced tetrahydrobiopterin, are

N

10

H.

i S-C-C-CH,

H

Dihydrobiopterin (H2B)

NH

NH

OH

n

5

O
H.

OH
N

65

pteridine compound in the biological sample is in its fully
oxidized State, and that pteridine compound concentration is
then detected. The pteridine compound which is oxidized to
its fully oxidized state is selected from the group consisting of
6,7-dimethylpterin, 6-biopterin, D-(+)-neopterin, 6-hy
droxymethylpterin, pterin, isoxanthopterin, Xanthopterin,

pterin-6-carboxylic acid, oncopterin ((N'-(3-aminopropyl)

biopterin), and two or more of said compounds. In other
words, in various embodiments one might focus on only one
Such pteridine compound; and in other embodiments one
might focus on several or all such pteridine compounds. For
best results, all of these eight compounds are fully oxidized.
Also, in this sense it is understood that each of these eight
listed compounds may exist in the sample initially in a less
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oxidized state having a different name. So, for example, when
the process is described as oxidizing at least about 90 wt % of
the biopterine concentration to its fully oxidized state, it is to
be understood that it is described this way for clarity pur
poses, and this encompasses and requires oxidizing at least
about 90 wt % of the concentration of all the lower oxidized

forms thereof (e.g., tetrahydropteridine and dihydropteri
dine) to biopterine. The description therefore encompasses
oxidizing at least about 90 wt % (95 wt %, or 99 wt %) of the
lower oxidized forms of 6,7-dimethylpterin to the fully oxi
dized state; oxidizing at least about 90 wt % (95 wt %, or 99
wt %) of the lower oxidized forms of 6-biopterinto the fully
oxidized state; oxidizing at least about 90 wt % (95 wt %, or
99 wt %) of the lower oxidized forms of D-(+)-neopterin to
the fully oxidized state; oxidizing at least about 90 wt % (95
wt %, or 99 wt %) of the lower oxidized forms of pterinto the
fully oxidized state; oxidizing at least about 90 wt % (95 wt
%, or 99 wt %) of the lower oxidized forms of isoxanthopterin
to the fully oxidized state; oxidizing at least about 90 wt % (95
wt %, or 99 wt %) of the lower oxidized forms of xanthopterin
to the fully oxidized state; oxidizing at least about 90 wt % (95
wt %, or 99 wt %) of the lower oxidized forms of pterin-6carboxylic acid to the fully oxidized state; oxidizing at least
about 90 wt % (95 wt %, or 99 wt %) of the lower oxidized

forms of oncopterin ((N'-(3-aminopropyl) biopterin) to the

fully oxidized state.
The pteridines in the biological sample, e.g., urine sample,
may be oxidized by a variety of oxidation reagents, for
example, iodine, peroxide, persulfate, nitrates, chlorites, per
manganate, or iron(III) chloride. Oxidation of the pteridines
to their fully oxidized state is preferably carried out by expos
ing the biological sample containing pteridines to iodine. In
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from between about 10 kV and about 30 kV.
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Some embodiments, the oxidation solution contains elemen
tal iodine and an iodine salt. Oxidation methods are disclosed

in Trehan (J. Clin. Biochem. and Nut., 14, 195-203, 1993),
Sawada (Clin. Chim. Acta, 138, 275-282, 1984), and Gold
berg (J. Vet. Med. A., 34,481-486, 1987 and Pteridines, vol 1,
29-35, 1989).
In preferred embodiments, the oxidizing Solution com
prises 4.0% (w/v) potassium iodide and 2.0% (w/v) iodine.
The oxidizing solution may be prepared in bulk and stored in
a dark container and sealed within a secondary container
(such as aluminum foil) to avoid photo degradation of iodine.
In preferred embodiments, the pteridines are oxidized by
contacting the biological sample containing pteridines with a
composition comprising 4.0% (w/v) potassium iodide and
2.0% (w/v) iodine in a concentration that is sufficient to
quantitatively oxidize the pteridines that exist in the sample in
a reduced form. In preferred embodiments, the iodine con
centration is present in a stoichiometric excess over the esti
mated concentration of pteridine that is in a reduced form.
Preferably, the molar ratio of iodine to the estimated concen
tration of pteridine in the sample that is in a reduced form is at
least about 1:1, such as at least about 2:1, preferably at least
about 4:1.

In some embodiments, oxidation of the pteridines in the
biological sample occurs under alkaline conditions. The pH
of the biological sample is adjusted to an alkaline condition
because pteridines are only sparingly soluble or insoluble in
acidic pH. The pH of the biological sample may be adjusted
to an alkaline pH between about 7.5 and about 11, preferably
between about 8 and about 10, even more preferably between
about 9 and 9.8. Standard alkaline adjustment agents may be
used. Such as Sodium hydroxide, potassium hydroxide, and
amines such as tetramethylammonium hydroxide.
In general, oxidation occurs to an extent Sufficient to quan
titatively oxidize the pteridines in the sample to their fully
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oxidized state after about 30 minutes exposure to the oxidiz
ing agent. Due to the potential photo activity of pteridines and
urine, oxidation preferably occurs in dark environments.
After oxidation and alkalinization, the sample is centri
fuged. A biological sample that is subjected to alkalinization
and oxidation generally contains insoluble material. The
sample is centrifuged for a duration and centrifugal force
Sufficient to separate the insoluble materials into a solid plug
on the bottom of the vessel. The liquid is separated from the
solid. The supernatant liquid is then diluted with sample
buffer generally at a ratio of at least 1 part sample to 1 part
sample buffer, but the dilution may be greater if the pteridine
concentration is too high for the detector.
II. Capillary Electrophoresis
Capillary electrophoresis (CE) generally involves the
application of high Voltages across buffer-filled capillaries to
achieve separations by their charge and frictional forces and
hydrodynamic radius. Operation of a high-performance cap
illary electrophoresis (HPCE) system involves application of
a high Voltage across a narrow bore capillary. The separation
of compounds by capillary electrophoresis is dependent on
the differential migration of analytes in an applied electric
field. Voltages forestablishing the electric field generally vary
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The capillaries used are normally fused silica capillaries
covered with an opaque external polymer protective coating
to give them increased mechanical strength. A Small portion
of this coating is removed to form a window for detection
purposes. Removal of the polymer protective coating renders
the capillary detection window transparent to visible light
wavelengths and light wavelengths of the excitation source.
The window is aligned in the optical center of the detector.
Capillaries are typically between about 25 cm and about 200
cm long, preferably between 25 cm and 100 cm long. Prefer
ably, the window is between about 15 cm and about 100 cm
from the sample introduction point, thereby defining an effec
tive length of the capillary of sufficient length to separate the
compounds of interest. Capillary inner diameters may vary
from about 25 micrometers to about 300 micrometers. In
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embodiments of the present invention, the capillary inner
diameter is preferably between about 25 micrometers and
about 200 micrometers. Successful separations have occurred
in capillaries having internal diameters of 50 micrometers
and 75 micrometers. On standard commercial high-perfor
mance capillary electrophoresis (HPCE) instruments, the
capillary is typically held in a housing device as a cartridge to
facilitate ease of capillary insertion into the instruction and to
protect the delicate detection window area.
The capillary is filled with a buffer solution which conducts
current through the inside of the capillary. The ends of the
capillary are dipped into reservoirs filled with the buffer.
Electrodes made of an inert material Such as platinum are also
inserted into the buffer reservoirs to complete the electrical
circuit. Preferred operating buffers include tris(hydroxym
ethyl)aminomethane (“Tris'), 2-N-(morpholine)ethane
Sulfonic acid, N-(2-acetamido)iminodiacetic acid, pipera
Zine-N,N'-bis(2-ethanesulfonic acid, N(2-acetamido)-2aminoethanesulfonic

60

acid,

(2-aminoethyl)trimethyl

ammonium chloride hydrochloride, N.N-bis(2-hydroxy
ethyl)-2-aminoethane sulfonic acid, N2-hydroxy
ethylpiperzine-N'-2-ethanesulfonic

(hydroxylmethyl)methylglycine,
hydroxyethyl)-glycine,

acid,

N-tris

N N-bis(22-(N-cyclohexylamino)

ethanesulfonic acid, and mixtures thereof.
65

In some embodiments, the running buffer is a Tris buffer in
a concentration between about 0.05 Mandabout 0.2M, pref
erably about 0.1 M. The running buffer may additionally
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comprise borate, phosphate, or acetate in a concentration
sufficient to carry a current, such as between about 0.01 Mand
about 0.15 M.Tris-borate is a commonly used running buffer.
The running buffer may additionally comprise a complex
ing agent, such as ethylenediamine tetraacetic acid. It has
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comprising distinct peaks representing the migration time of
each pteridine in the sample. FIG. 1 is a schematic design
detailing the optical setup of the apparatus according to one
embodiment of the invention.

In general, LIF comprises irradiating the pteridine contain
ing running buffer with radiation within the wavelength range

further been found that the concentration of EDTA in the

buffer influences the separation of pteridines while in a free
condition. Specifically, concentrations of up to about 2 mM
EDTA enhances the separation of the two isomers, isoxan
thopterin and Xanthopterin.
The pH of the running buffer is generally between about
7.0 and about 12.0, preferably between about 8.0 and about
10.0, such as between about 9.0 and about 10.0. The running
buffer is generally from 8.0 to 10 to assist in the systematic
isolation of specific pteridines within the compounds of inter
est. Standard alkaline adjustment agents may be used, such as
Sodium hydroxide, potassium hydroxide, and amines Such as
tetramethylammonium hydroxide. The optimized condition
for separating urinary pteridines uses a running buffer with
pH of 9.63+0.02.
Temperature has also been found to influence the separa
tion of pteridines due to the change of mobility of the pte
ridines at various temperatures. The temperature of the pte
ridines during separation therefore should be in the range of
from about 18°C. to 30°C., with from about 22°C. to 25°C.

being preferred. The temperature may be regulated using a
cooling system to counteract Joule heating caused by the
resistance of the Voltage through the electrolyte system.
Cooler systems that effectively counteract Joule heating are
preferred since the analyte peaks are sharper and more

between 270 nm and 450 nm, such as between about 270 nm.
and about 350 nm or between about 300 nm and about 450
10

Some embodiments, the excitation source for Laser Induced
15

such laser is an Inca brand laser available from Xiton Photo

about 1 mW, at least about 10 mW, such as between about 1
mW and about 40 mW, between about 10 mW and about 40
25

30

35

40

45

50

55

60

III. Laser Induced Fluorescence

In the method of the present invention, the electrophoreti
cally separated pteridines are detected via lased induced fluo
rescence. The fluorescence produced by the sample is isolated
and plotted with respect to time to form an electropherogram

mW, preferably between about 20 mW and about 25 mW. The
excitation source may emit polarized or non-polarized light.
In preferred embodiments, the excitation source emits non
polarized light. Non-polarized laser light is preferred since
non-polarized light scatters less light upon impinging the
capillary wall.
The CE-LIF apparatus comprises a filtration device
capable of transmitting laser light of a desired wavelength. In
general, the filtration device comprises aband pass filter that
isolates and transmits the desired wavelength and attenuates
all other wavelengths. In some preferred embodiments, the
desired laser wavelength is 325 nm. A band pass filter suitable
for the apparatus of the present invention is a 325 nm band
pass filter (Ealing, Holliston, Mass.; model UG-11). Several
other types of band pass filters are available from Thorlaps of
Newton, N.J., for example part number FL355-10 (laser line
filter, CWL=355=/12 nam, FWHM-10–/-2 nmi; family: 0.1"
UV laser line filters). Ultraviolet scan data reveal that some
pteridines absorb from about 200 to about 360 nm, with a
Aaround 350-360 for most. The excitation wavelengths of
interest in the present method are therefore in the range of
about 300 to about 450 nm.

between about 20 kV and about 30 kV, such as between 24

and 26 kV. In a capillary having an effective distance between
the sample injection point and the detection window between
about 20 cm and about 40 cm, effective separation of pte
ridines in a biological sample can be achieved in 10 to 20
minutes. Empirical results to date indicate that separation
efficiency of greater than 100,000 theoretical plates may be
achieved using the capillary electrophoretic separation
method of the present invention.

Fluorescence (LIF) is a helium-cadmium laser operating in
the range of about 320 to 330 nm, with about 325 nm being
most preferred. One such laser is the Melles Griot
Omnichrome Series-74, 325 nm laser (HeCd laser, 35 mW
power, Carlsbad, Calif., USA). In some embodiments, the
excitation source is a Solid state laser in the wavelength range
of about 300 nm to 450 nm, preferably about 350 nm. One
nics GmbH of Kaiserlautern, Germany. In preferred embodi
ments, the excitation source has a power output of at least

resolved.

The electrophoretic separation of pteridines in the biologi
cal sample begins with sample injection. The sample is pre
pared, e.g., oxidized and alkalinized, as described above and
injected into the capillary via gravimetric injection, electro
kinetic injection, pressure, or Suction. Even though electro
kinetic injections can provide an on-line concentration of
analytes at low concentrations, it is a very selective injection
technique and the amount of analyte injected is dependent on
the electro mobility of the analyte, which makes the injection
biased toward analytes having high electromobilities, thereby
overweighting the concentrations thereof in the analyzed
sample. Relatively, gravimetric injection is a less biased tech
nique, where a true composition of the sample may be
observed at the expense of a more diluted injection. To
accomplish gravimetric injection, the sample is raised higher
than the waste reservoir. The sample injection end of the
capillary is placed into the sample vial and through capillary
and siphoning action, the sample is introduced. Experimental
results indicate that injection for 10 sec at a height of 17.5 cm
introduced roughly 5-7 nL of sample.
In preferred embodiments, separation of pteridines from
the sample occurs at electrophoretic potential (EP) in a range

nm, to induce fluorescence of the pteridines when a plug of a
particular pteridine passes through the detection window. In
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The CE-LIF apparatus comprises an optical system for
focusing the filtered, non-polarized laser onto the detection
window of the capillary, the pathway by which the intended
sample is separated and exposed to the filtered, non-polarized
laser via a detection window on the capillary. The optical
system comprises a focal length. Preferably, the focal length
is as short as possible to reduce the amount of scatter or stray
layer. In preferred embodiments, the optical system com
prises, for example, a 2.0 cm focal length lens.
The high powered laser may have substantial scatter light.
In view thereof, the CE-LIF apparatus preferably comprises
an optical iris diaphragm positioned between the focal lens
and the detection window of the capillary. The optical iris is
positioned to cut off scatter light from the laser. A currently
preferred iris is a 25 mm (outer diameter) High Performance
Zero Aperture Series Iris Diaphragm available from Edmund
Optics of Barrington, N.J. The iris is not narrowly critical to
carrying out the invention; it reduces background noise to
make the analysis more sensitive. It should be large enough to
block all of the potential background and scattered light and
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While
the
invention
has
been
described in connection with
close sufficiently to make the effective field of view small
enough to allow only the width of the laser or emitting fluo specific embodiments thereof, it will be understood that the
rescence through.
inventive methodology is capable of further modifications.
The CE-LIF apparatus comprises a sample holder with a This patent application is intended to cover any variations,
detection window that facilitates the mounting of an electro- 5 uses, or adaptations of the invention following, in general, the
phoresis capillary.
principles of the invention and including such departures
The CE-LIF apparatus comprises a capillary electrophore from the present disclosure as come within known or custom
sis device as described above that is capable of separating the ary practice within the art to which the invention pertains and
specific compounds of interest (pteridines) within the bio as may be applied to the essential features herein before set
logical sample and delivering the sample to the detection 10 forth and as follows in Scope of the appended claims.
window of the capillary mounted within the sample holder.
Having described the invention in detail, it will be apparent
The CE-LIF apparatus preferably comprises a confocal that modifications and variations are possible without depart
lens having greater than 10x magnification placed in the ing from the scope of the invention defined in the appended
range of 45 to 90 degrees (90 degrees being preferred) from claims.
the laser path to collect and focus fluorescence emission from 15
EXAMPLES
the sample. In preferred embodiments, the confocal lens has
greater than 20x magnification, greater than 30x magnifica
tion, or even greater than 40x magnification, such as 43x
The following non-limiting examples are provided to fur
magnification. An exemplary confocal lens is available from ther illustrate the present invention.
Bausch and Lomb, 0.6 NA, 40x.
Example 1
The CE-LIF apparatus preferably comprises a second fil
tration means for filtering fluorescence generated by impuri
ties and other sources of fluorescence. The second filtration
The following example describes a high performance cap
device is used to transmit fluorescence from pteridines while illary electrophoresis (HPCE) separation of pteridines in a
blocking fluorescence from non-pteridine sources. The sec 25 biological sample with laser-induced fluorescence (LIF)
ond filtration means may be a bandpass filter designed to detection method (HPCE-LIF) for quantitative analysis of
transmit pteridine fluorescence. The wavelengths transmitted pteridines in urine samples. HPCE-LIF was used to investi
are generally between 400 and 539 mm. Such abandpass filter gate pteridine level patterns in 38 urine samples from a variety
of cancer patients. Some types of cancer were not studied
is available from Ealing, model 35-532.
The CE-LIF apparatus preferably comprises a physical 30 mainly due to the unavailability of urine samples and not the
optical iris diaphragm located between the bandpass filter/ limitation of the technique. In order to assure that the pteri
confocal lens and the fluorescent light collection device. The dine levels represent the physiological concentration, the
iris diaphragm removes any scattering either from the filtered amount of pteridines was reported here as a ratio of pteridine
non-polarized laser or from any fluorescence generated by the to creatinine See Shi H. Ma Y., Ma Y. A Simple and Fast
device. This iris is typically the same as the optical iris dia 35 Method to Determine and Quantify Urinary Creatinine, Anal.
phragm positioned between the focal lens and the detection Chim. Acta., 1995, 312, pp. 79-83.
Materials and Methods.
window of the capillary.
Chemicals.
The CE-LIF apparatus comprises a detection means for
Pteridine standard solutions of 6-biopterin, D-(+)-neop
detecting the filtered fluorescence emission generated by the
pteridines in the samples of interest. A preferred light detec 40 terin, pterin, isoxanthopterin, Xanthopterin pteridine were
tion means is a photomultiplier tube, which is an extremely purchased from Sigma-Aldrich (St. Louis, Mo.). Standard
sensitive detector of light in the ultraviolet, visible, and near solutions of 6,7-dimethylpterin and 6-hydroxymethylpterin
infrared ranges of the electromagnetic spectrum. A commer were purchased from Schircks Laboratories (Jona, Switzer
cially available PMT is a Hammatsu PMT. Type R928, No. land). Boric acid and Tris(hydroxymethyl)aminomethane
IG6957.
45 were purchased from Sigma-Aldrich (St. Louis, Mo.). EDTA
The current signal from the fluorescent light detection disodium salt, iodide, potassium iodine, sodium hydroxide
device is preferably converted to a voltage via a current to and sodium phosphate dibasic were purchased from Fisher
Voltage (I to V) converter, which communicates the raw out (Fair Lawn, N.J.). Ultrapure water was obtained using a
put of electrons produced in the fluorescent light detection Milli-Q Advantage(R) A10 and Millipore Elix(R) water purifi
device produced by fluorescence from the compounds of 50 cation system.
interest undergoing fluorescent decay to the digital input of
pH Measurement.
the device collecting the output.
All pH measurements were performed on an Accumets(R)
The CE-LIF apparatus preferably comprises a control Excel XL-15 pH meter that was standardized using pH stan
means for independently controlling the stations of the laser dards 4, 7, and 10 (Fisher ScientificTM). Standard creatinine
focal lens, capillary mount, collection lens and detector to 55 for creatinine analysis was purchased from Sigma-Aldrich.R.
prevent any mechanical cross-talk from one stage to the oth (Milwaukee, Wis.).
Buffer Preparation.
ers that may adversely affect the resulting data.
The combination of a physical optical iris diaphragm
A 0.1 M Tris/0.1 Mborate/2 mM EDTA running buffer was
placed between the focal lens and the capillary detection prepared and pH was adjusted to 9.63+0.02 using 2.0 M
window, a high magnification confocal lens, and a physical 60 NaOH. A 50 mM aqueous solution of NaHPO, sample
optical iris diaphragm placed between the confocal lens and buffer was prepared and pH was adjusted to 7.70+0.02 using
the light collection device provides an extremely stable base concentrated phosphoric acid. This was used to dilute both
line, which in turn yields high signal to noise ratios (S/N) and standards and samples. A 15 mM. KHPO solution was pre
low limits of detection. According to some empirical results, pared and pH was adjusted to 6.4 using 1.0 M NaOH. This
the baseline is less than 1 mV, which enables low limits of 65 was used as the running buffer for creatinine analysis. The
detection. The limits of detection reported in the below creatinine sample dilution buffer was prepared in exactly the
examples were at S/N=5.
same way as the running buffer except that 2% EDTA was
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present in sample dilution buffer. EDTA was used to complex
the metalions in the urine sample so that these ions would not
form complexes with creatinine. All the buffers were filtered
with a 0.45 um membrane and degassed before use.
Standard Preparation.
To prepare pteridine standard Solutions, 2 mg of pteridine
standard was dissolved in a solution consisting of 0.3 mL of
1.0 M sodium hydroxide and 9.7 mL of sample buffer. A
standard mixture was then prepared by combining equal
molar concentrations of each standard and diluted to a final
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concentration of 5.0x10M with the sample buffer. A dilu

tion series of this stock solution was used to generate calibra
tion curves. Standard creatinine stock Solution was prepared
by dissolving 50 mg creatinine into 50 mL sample dilution
buffer to make the creatinine concentration 100 mg/dL. This
standard stock solution was diluted to an appropriate concen
tration with the sample dilution buffer.
Oxidizing Solution Preparation.
The oxidizing solution consisted of 4.0% potassium iodide
and 2.0% iodine (w/v). It was prepared by dissolving 0.6008
g of KI in 15 mL of Milli-Q water. Once the KI was dissolved,
0.3025g of I was added to the solution. The solution was then
stirred (for about 1 h) until the I was completely dissolved.
The final Solution was stored in an amberglass vial, and the
cap was wrapped with ParafilmR). The vial was wrapped with
aluminum foil to avoid photo degradation of the iodine.
Urine Sample Preparation.
Urine samples from cancer patients who did not undergo
chemical or radiation therapy were obtained from Ellis Fis
chel Cancer Center, Columbia, Mo. The normal urine

samples were collected from student volunteers at Missouri
S&T who did not take any medications including vitamin
Supplements. The demographic distribution of cancer
patients and normal Subjects were mainly from nearby cities.
The age distribution of cancer patients was from 26-70 y, and
the range for normal Subjects was 22-45 y. There was no
dietary or exercise restriction performed among the control
group or the cancer patients. The urine from the cancer
patients represented breast (12), lung (9), colon (4), rectal (2),
pancreatic (1), ovarian (3), non-Hodgkins lymphoma (4),
esophageal (4), bladder (1), and kidney (1) cancers. All the
samples were stored in a freezer at -80° C. Prior to analysis,
the samples were removed from the freezer and brought to
room temperature. A 1000 uL aliquot of urine sample was
taken using a micropipette and placed in a 1.5 mL yellow
microcentrifuge tube. Then 400 uL of the oxidizing solution
and 100 uL of 2.0 M NaOH were added to the sample and
mixed well. The sample mixture was incubated at 4°C. for 30
min and centrifuged at 5000 rpm for 20 minat 4°C. Then 500
LL of the Supernatant was placed in a new vial, and 500LL of
sample buffer was added to it. It was mixed thoroughly and
injected directly into the CE for analysis. Further dilutions
were made in some samples.
Capillary Electrophoresis Laser Induced Fluorescence
System (CE-LIF).
A home-built capillary electrophoresis LIF system was
used for this study. A depiction of the device is provided in
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FIG.1. A Melles Griot Omnichrome Series-74, 325 nm laser

(HeCd laser, 35 mW power, Carlsbad, Calif., USA) was used
for excitation. The stray and scattered light from the nonpo
larized laser were removed using a 325 nm band-pass filter
(Ealing, Holliston, Mass.; model UG-11). The laser was
focused on the capillary window with a 2.0 cm focal length
lens. Prior to impinging the detection window of the capillary,
the laser beam passed through an iris, which remove Scatter
light from the laser. The first iris is positioned to provide the
only pathway for light to enter the system, and the adjustment
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is the diameter of the opening. It is reduced to permit only the
laser beam through. The second iris is positioned to provide
the only pathway that fluorescence can get to the detector
(PMT). Again, the adjustment is the diameter of the opening
to reduce the effective field of view to only include light
passing through the inner diameter of the capillary, which
contains the sample and emits the fluorescence.
The fluorescence emission was collected by a microscopic
objective and focused onto a R982 Hamamatsu photomulti
plier tube (Bridgewater). The microscopic objection com
prises a confocal lens having 40 or 43X magnification, which
choice depended upon the experimental conditions. Back
ground noise was minimized using a band-pass filter (400
539 nm, Ealing, model 35-532). A second iris is placed after
the band pass filter and confocal lens (43X magnification) in
order to reduce scatter light from the capillary. The resulting
output current from the photomultiplier tube was converted to
a Voltage signal through a home-built current-to-voltage con
Verter. The analog signal was then digitalized though a Log
ger Pro analog-to-digital converter (Verniers Software and
Technology, Beaverton, Oreg.). The data were collected
using Logger Pro 3.1 data collection Software.
Creatinine Analysis.
Creatinine analysis was performed following a method that
was previously developed in our group. See Shi H. MaY., Ma
Y., A Simple and Fast Method to Determine and Quantify
Urinary Creatinine, Anal. Chim. Acta., 1995, 312, pp. 79-83.
A Beckman P/ACE capillary electrophoresis instrument
equipped with ultraviolet absorbance was used for creatinine
analysis. The detection wavelength was set at 214 nm. The
capillary column (Polymicro Technologies, Phoenix, Ariz.)
used was 60 cmx50 um inner diameter fused silica tubing
with an effective length of 35 cm. Electrophoresis was carried
out at 20 kV. Urine samples were diluted with sample dilution
buffer and directly injected into the HPCE column. The data
were collected and processed by 32 Karat Software ver, 5.0
(Beckman, Inc.). Peaks were identified by both retention time
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Pteridine Analysis Using CE-LIF.
A70 cm lengthx50um inner diameter fused silica capillary
(Polymicro Techniques, Phoenix, Ariz., USA) was used for
separation. First, the new capillary was rinsed with 1.0 M
NaOH for 15 min, followed by Milli-Q water for 5 min. Next,
it was rinsed with 1M HCl for 15 min, with Milli-Q water for
5 min, and finally with running buffer for 15 min. A 1 cm
section of the polymer coating was burned off at 35 cm from
the cathode end, forming the detection window and leaving an
effective capillary length of 35 cm. Samples were injected
into the capillary by the gravimetric method. Samples were
injected 17.5cm from the top of the sample to the instrument
table with an injection time of 10 s. Electrophoresis was
carried out at 26 kV (371 V/cm) for 20 min. After each
injection, the capillary was regenerated by flushing with 0.2
M NaOH for 1 min, followed by a 2 min water rinse, and
finally by a 2 min running buffer rinse. The individual pteri
dine peaks in the urine samples were identified by retention
time comparisons and standard addition and obtained from
the Logger Prosoftware.
Statistical Analysis.
Pteridine concentrations were determined by linear regres
sion against experimentally generated calibration curves. The
basic statistical information Such as mean, variance, and
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pooled variance of each pteridine for both cancer and normal
urine samples were calculated by Minitab Software. Statisti
cal hypothesis testing was conducted to analyze the data. The
null hypothesis was that the mean pteridine levels in cancer
samples are lower than or equal to those in normal urine. The
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alternative hypothesis was that mean pteridine levels in can
cer samples are higher than those in normal samples. The P
values (last raw in Table 2) were calculated for all samples.
The null hypothesis was rejected, and the results demonstrate
that the alternative is significant at a 5% significance level if 5
the P values0.05.
TABLE 2
Basic Statistical Summaries of Each
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Pteridine for Cancer and Normal Urine Samples
Pteridine

Mean Cancer

6,7-

6

dimethyl

hydroxymethyl

D-(+)-

pterin

6-biopterin

pterin

neopterin

7.41E-04

8.96E-04

4.81E-04

1.14E-O3

2.79E-05

1.14E-04

4.83E-OS

2.37E-04

8.81E-O6

2.67E-06

9.2OE-07

1.16E-05

3.3OE-09

114E-08

1.57E-09

1.2OE-07

6.15E-06

1.87 E-06

6.43E-07

8.16E-06

15

(n = 38)
Mean Normal

(n = 17)

Variance
Cancer
Variance
Normal
Pooled
Variance
t Stat

P (T<= t)

O.986

1958

1849

1079

O.164

O.O28

O.O3S

O.143

25

Pteridine
Pterin-6-

Mean Cancer

Pterin

Xantho
pterin

carboxylic
acid

6.OOE-04

3.37E-O2

S.S9E-03

2.54E-04

175E-04

106E-O3

1.13E-O3

1.25E-04

S.28E-07

1.1OE-03

3.94E-OS

9.109E-08

30

(n = 38)
Mean Normal

graph had a linear range from 0 to 20 mg/dL and R was

0.9819. Creatinine levels in cancer patients and healthy sub
jects were shown in FIG. 13.
Table 2 provided basic statistical information such as
mean, variance, and pooled variance of each pteridine for
both cancer and normal urine samples. The key objective of
this work was to determine whether there is any significant
difference between levels of pteridine in cancer urine samples
and those in normal urine samples. FIG. 3 showed the box
plot of 6,7-dimethylpterin. In the urine samples of cancer
patients, 3 outliers are disregarded, there was no significant
difference in levels of 6,7-dimethylpterin in cancer and nor
mal samples. The P value of 6-biopterin was 0.028. So the
mean value of 6-biopterin in the cancer samples was signifi
cantly greater than that in the normal samples (FIG. 4). FIG.
5 indicated that, even after the outliers were removed, the

20

one tail

Isoxantho
pterin

18
first and the pterin-6-carboxylic acid eluted last. FIGS. 3-12
show the box plots of various pteridines in samples from both
cancer patients and healthy Subjects. Creatinine calibration
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6-hydroxymethylpterin level in cancer patients was higher
than the normal (P=0.035). FIG. 6 showed that the D-(+)neopterin level was higher in cancer patients than in normal
subjects but P value was 0.143. Therefore, the D-(+)-neop
terin level in cancer urine samples was not significantly
greater than normal because D-(+)-neopterin variance was
higher in cancer. The pterin levels in cancer were significantly
higher than normal (P=0.011) (FIG. 7).
In both cancer and normal urine samples, levels of Xantho
pterin and isoxanthopterin levels were higher than those of
other pteridines, as indicated by the y axes of the box plots.
The box plot for Xanthopterin and isoxanthopterine (FIGS. 8
and 9) showed that levels in the cancer urine samples were

much higher than in the normal urine samples (P-8.7x10.
and 2.8x10, respectively). Hanet al. previously showed that

lower isoxanthopterin levels in cancer patients compared to
the normal. See Han F., Huynh B. H., Shi H., Lin B., MaY.,
Pteridine Analysis in Urine by Capillary Electrophoresis
2.93E-08
S.66E-07
1.47E-O6
198E-08
Using Laser-Induced Fluorescence Detection, Anal. Chem.
1999, 71, pp. 1265-9. But they analyzed only 9 cancer patient
3.78E-07
7.68E-04
2.79E-0S
6.957E-08
40 urine samples and this may be due to outliers present in the
2.373
4.040
2.891
1682
data. The pterin-6-carboxylic acid was not significant
P (T<= t)
O.O11
8.67E-OS
O.OO3
O.049
(P=0.049) (FIG. 10).
one tail
A comparison of the P values of each pteridine demon
strates that Xanthopterin and isoxanthopterin were much
The standard mixture of 8 pteridines was first injected into 45 lower than those of the other pteridines. Thus, their levels in
the CE, and the elution order was obtained. The detection
breast cancer (n=12) and lung cancer (n=9) urine samples
limit, linear equations and R values are given in Table 3.
were checked (FIGS. 11 and 12). Table 4 showed the P values
calculated for various combinations. Xanthopterin and isox
TABLE 3
anthopterin levels cannot be used to differentiate lung cancer
50 from breast cancer. These biomarkers were significantly high
Calibration Data for Each Pteridine
in breast and lung vs. normal (P<0.05).
(n = 17)

Variance
Cancer
Variance
Normal
Pooled
Variance
t Stat

Pteridine

6,7-dimethyl
pterin
6-biopterin

Limit of

Linear Equations of

Detection

Calibration Curves

2.5 x 100 y = 1.2383 x 10°X + 0.9642
2.5 x 109 y = 9.2704 x 10X + 0.3174

6-hydroxy2.5 x 100
D-(+)-neopterin 2.5 x 109
Pterin
2.5 x 109
Isoxanthopterin 2.5 x 109
Xanthopterin
2.5 x 100
Pterin-64.72 x 109
methyl pterin

carboxylic acid

y = 7.6386 x 10X + 0.3339
y = 9.2866 x 10X + 0.2902
y = 7.9057 x 10X + 0.3014
y = 3.6299 x 10X + 0.0897
y = 6.5796 x 10X + 0.0863
y = 1.6335 x 10X + 0.3788

R2

0.98.28 ss
O.9911

O.9923
O.9947
O.9936
0.9987 60
O.9988
O.9988

TABLE 4

Xanthopterin and isoxanthopterin P values for various
combinations of lung cancer, breast cancer, and
normal urine samples
Pteridine

Combination

Xanthopterin

Lung Cancer v. Breast Cancer
Lung Cancer v. Normal

O.1311
8.S1E-OS

Breast Cancer v. Normal

4.18E-OS

Lung Cancer v. Breast Cancer
Lung Cancer v. Normal

O.04898
O.OOO287

Breast Cancer v. Normal

O.OO7288

Isoxanthopterin

P

The electopherogram is shown in FIG. 2. The number of 65
This work analyzed 8 pteridines in urine samples from
theoretical plates for the separation was determined to be
130,000. FIG. 2 showed that the 6,7-dimethylpterin eluted cancer patients and healthy Subjects. Some pteridine levels in
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the urine samples of the cancer patients were higher than
those of healthy subjects. More specifically, 6-biopterin,
6-hydroxymethylpterin, pterin, Xanthopterin and isoxantho
pterin levels in cancer samples were significantly higher than
normal. Also, levels of Xanthopterin and isoxanthopterin in
both cancer patients and healthy Subjects were higher than
other pteridines. The foregoing demonstrates that the inven
tion is effective for using pteridines as biomarkers for early
cancer Screening.
Example 2
The foregoing method was also performed to analyze for
cancer by detection of oncopterin. Cancer and cancer-free
urine samples were analyzed and plotted as shown in FIG. 14.
The experimental conditions were as follows: Running
buffer: 0.1 M Tris-0.1 Mborate-2 mM EDTA, pH 9.63; Cap
illary: 50 mm i.d.x70 cm (35 cm effective column length):
Injection: gravimetric (17.5 cm from the of the sample to the
instrument table and the injection time was 10 seconds).
Running voltage: 371 V/cm; LIF detection at 325 nm/445 nm.

10

15

(ex/em); concentration of each pteridine standard: 10x10

M. FIG. 14 shows these eight known peaks in the cancer
samples and has them labeled 1-8: 1) 6,7-dimethylpterin; 2)
6-biopterin; 3) D-(+)-neopterin; 4) 6-hydroxymethylpterin;
5) Pterin; (6) isoxanthopterin; 7) xanthopterin; (8) carboxyp
terin. FIG. 14 also shows two peaks not identified with any of
(1) through (8).
Previous work shows that oncopterin is elevated in patients
with cancer. Since this experiment ran cancer and control
samples side-by-side, one would expect to see a distinct dif
ferent between the electropherograms. The peak between the
peaks labeled 1 (6.7 DMP) and 2 (biopterin) is expected to
identify oncopterin in view of the structural similarity
between oncopterin and biopterin. It is expected this will be
confirmed by analysis of an oncopterin standard. Consistent
with this identification is that propylamine which differenti
ates oncopterin from biopterin could shift its elution time in
an unpredictable manner, which would manifest itself in the
second peak marked with an arrow in FIG. 14.
When introducing elements of the present invention or the
preferred embodiments(s) thereof, the articles “a”, “an',
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phoresis using laser-induced fluorescence (CE-LIF) to
cause the oxidized portion of said concentration of said
oncopterin (N2-(3-aminopropyl) biopterin) to emit fluo
rescent light, detecting the emitted fluorescence light,
and analyzing the emitted fluorescence light to deter
mine the concentration of the oncopterin (N2-(3-amino
propyl) biopterin) in the biological sample; and
comparing the concentration of oncopterin (N2-(3-amino
propyl) biopterin) in the sample to an expected concen
tration of oncopterin (N2-(3-aminopropyl) biopterin)
for either a healthy or cancer-bearing mammal of the
same species;
wherein the CE-LIF comprises directing laser light
through a filter, a focal lens, and an iris of a first optical
system and into an electrophoresis capillary containing
the biological sample to irradiate and cause fluorescence
from the biological sample; and receiving fluorescence
emission from the biological sample through a second
optical system comprising a confocal lens having a mag
nification greater than 20x and an iris which focus emit
ted fluorescence onto a photomultiplier tube as a light
collection device for collecting fluorescent light emitted
from the pteridine in the biological sample.
2. The method of claim 1 wherein the biological sample is
a urine sample.
3. The method of claim 1 wherein the subjecting the sample
to CE-LIF comprises:
injecting the biological sample containing the oxidized
portion of pteridine into a capillary;
electrophoretically separating the oxidized portion of pte
ridine in the capillary by applying an electric field hav
ing a minimum voltage of 10 kV; and
irradiating the separated sample with non-polarized laser
light from an excitation source having a power output of
at least 1 mW.

4. The method of claim 1 wherein the treating the biologi
cal sample with the oxidizing agent is in a concentration
sufficient such that at least about 95 wt % of said concentra
40

tion of said pteridine compound in the biological sample is in
its fully oxidized state.
5. The method of claim 1 wherein the treating the biologi
cal sample with the oxidizing agent is in a concentration

“the' and “said are intended to mean that there are one or

sufficient such that at least about 99 wt % of said concentra

more of the elements. The terms “comprising”, “including
and “having are intended to be inclusive and mean that there
may be additional elements other than the listed elements.
In view of the above, it will be seen that the several objects
of the invention are achieved and other advantageous results

tion of said pteridine compound in the biological sample is in
its fully oxidized state.
6. The method of claim 1 wherein the pteridine compound
concentration is quantitatively oxidized by contacting the
biological sample with elemental iodine.
7. The method of claim 1 wherein the biological sample is
combined with a sample matrix having a high ionic strength.
8. The method of claim 7 wherein the sample matrix is
phosphate buffer.
9. The method of claim 1 further comprising detecting
concentration levels of pteridine compounds other than onco
pterinto determine what type of cancer that the mammal may
develop.

45

attained.

AS Various changes could be made in the above composi
tions and processes without departing from the scope of the

50

invention, it is intended that all matter contained in the above

description and shown in the accompanying drawings shall be
interpreted as illustrative and not in a limiting sense.
What is claimed is:

55

1. A method for Screening for cancer in a mammal, the
method comprising:
obtaining a biological sample from the mammal;
treating the biological sample with an oxidizing agent in a
concentration sufficient such that at least about 90 wt %

10. The method of claim 1 wherein the CE-LIF causes the
60

of concentration of oncopterin (N2-(3-aminopropyl)
biopterin) in the biological sample is in its fully oxidized
State;

quantitatively measuring a concentration of oncopterin
(N2-(3-aminopropyl) biopterin) in said biological
sample by capillary electrophoresis-lased induced fluo
rescence by Subjecting the sample to capillary electro

65

oncopterin to be separated from other species in the biologi
cal sample matrix.
11. A method for Screening for cancer in a mammal, the
method comprising:
obtaining a biological sample from the mammal;
treating the biological sample with an oxidizing agent in a
concentration sufficient to fully oxidize oncopterin (N2
(3-aminopropyl) biopterin) in the biological sample:
quantitatively measuring a concentration of oncopterin
(N2-(3-aminopropyl) biopterin) in said biological

US 9,207,205 B2
21
sample by capillary electrophoresis-lased induced fluo
rescence by Subjecting the sample to capillary electro
phoresis using laser-induced fluorescence (CE-LIF) to
cause the oxidized portion of said concentration of said
oncopterin (N2-(3-aminopropyl) biopterin) to emit fluorescent light, detecting the emitted fluorescence light,
and analyzing the emitted fluorescence light to deter
mine the concentration of the oncopterin (N2-(3-amino
propyl) biopterin) in the biological sample; and
comparing the concentration of oncopterin (N2-(3-aminopropyl) biopterin) in the sample to an expected concen
tration of oncopterin (N2-(3-aminopropyl) biopterin)
for either a healthy or cancer-bearing mammal of the
same species;
wherein the CE-LIF comprises directing laser light
through a filter, a focal lens, and an iris of a first optical
system and into an electrophoresis capillary containing
the biological sample to irradiate and cause fluorescence
from the biological sample; and receiving fluorescence
emission from the biological sample through a second
optical system comprising a confocal lens having a mag
nification greater than 10x and an iris which focus emit
ted fluorescence onto a photomultiplier tube as a light
collection device for collecting fluorescent light emitted
from the pteridine in the biological sample.
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